Results 221 to 230 of about 234,728 (298)

Micro/Nanorobot for Drug Delivery—A Review of Material Selections

Advanced NanoBiomed Research, EarlyView.
This review explores material strategies for biomedical micro/nanorobots, emphasizing their roles in propulsion, navigation, drug delivery, and biodegradability. It highlights advancements in metallic, polymeric, and hybrid materials, while addressing clinical translation challenges such as toxicity, immune response, and manufacturability.
Xiaozhuo Wu, Bingyun Li, Malcolm Xing
wiley   +1 more source

Guidelines on primary healthcare for type 2 diabetes in China, 2025. [PDF]

Fam Med Community Health
Jia W, Zhu D, Guo L, Chen L, Cai C, Song J.   +5 more
europepmc   +1 more source

Redox‐Responsive Mitochondrial Delivery from Functionalized Vascular Stent Surfaces

Advanced NanoBiomed Research, EarlyView.
A redox‐responsive stent surface is engineered to deliver functional mitochondria in response to oxidative stress. Upon exposure to reactive oxygen species, grafted mitochondria are released, internalized by vascular cells, and restore mitochondrial function under stress.
Fang Tang, Brandon C. Applewhite, Bowen Wang, Bin Jiang   +3 more
wiley   +1 more source

Diabetes Monitoring in Pregnant Women with Type 1 Diabetes: Capillary Blood Glucose or Interstitial Fluid Glucose? A Case Control Study. [PDF]

Nutr Metab Insights
Jemai C, Htira Y, Salem A, Hadj Ali Z, Lajili O, Hedfi I, Ben Amara S, Ben Mami F.   +7 more
europepmc   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

13. Older Adults: Standards of Care in Diabetes-2026. [PDF]

Diabetes Care
American Diabetes Association Professional Practice Committee for Diabetes* .
europepmc   +1 more source

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Analysis of Single Particles of Amyloid Beta and α‐Synuclein With Seeded Amplification for the Diagnosis of Alzheimer's and Parkinson's Disease

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), are characterized by the pathological aggregation of specific proteins such as amyloid beta (Aβ) and α‐synuclein, respectively. Early detection of these protein aggregates in biological fluids could facilitate timely diagnosis and therapeutic ...
Alexandra Dybala, Marlene Pils, Oliver Bannach, Gültekin Tamgüney, Detlev Riesner   +4 more
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

7. Diabetes Technology: Standards of Care in Diabetes-2026. [PDF]

Diabetes Care
American Diabetes Association Professional Practice Committee for Diabetes* .
europepmc   +1 more source